🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/12/2016 | 76,70 | 76,94 | 74,09 | 75,32 | -3,58% | 3,72% | 2.569.100 |
| 06/12/2016 | 75,77 | 78,39 | 75,04 | 78,12 | +3,40% | 4,42% | 1.816.700 |
| 05/12/2016 | 76,13 | 77,33 | 75,25 | 75,55 | +0,07% | 2,73% | 2.588.600 |
| 02/12/2016 | 77,65 | 78,01 | 75,38 | 75,50 | -2,98% | 3,39% | 4.580.500 |
| 01/12/2016 | 81,85 | 82,53 | 77,75 | 77,82 | -4,64% | 5,84% | 2.662.600 |
| 30/11/2016 | 85,86 | 86,91 | 81,59 | 81,61 | -4,72% | 6,20% | 2.292.700 |
| 29/11/2016 | 86,21 | 87,50 | 84,40 | 85,65 | -1,44% | 3,60% | 1.745.500 |
| 28/11/2016 | 87,47 | 88,00 | 86,13 | 86,90 | -0,99% | 2,14% | 1.855.300 |
| 25/11/2016 | 87,71 | 87,97 | 86,29 | 87,77 | +0,49% | 1,92% | 814.400 |
| 23/11/2016 | 85,37 | 87,47 | 84,26 | 87,34 | +1,32% | 3,76% | 1.040.900 |
| 22/11/2016 | 89,32 | 89,75 | 85,40 | 86,20 | -3,20% | 4,87% | 1.765.600 |
| 21/11/2016 | 89,95 | 90,51 | 88,76 | 89,05 | -0,44% | 1,95% | 1.278.200 |
| 18/11/2016 | 90,94 | 91,48 | 89,00 | 89,44 | -1,93% | 2,73% | 1.265.400 |
| 17/11/2016 | 90,67 | 92,40 | 90,01 | 91,20 | +0,81% | 2,64% | 1.320.100 |
| 16/11/2016 | 92,58 | 93,06 | 90,43 | 90,47 | -2,78% | 2,84% | 1.487.000 |
| 15/11/2016 | 94,14 | 94,68 | 91,96 | 93,06 | -1,44% | 2,89% | 2.265.700 |
| 14/11/2016 | 92,33 | 94,51 | 89,64 | 94,42 | +2,63% | 5,27% | 2.485.100 |
| 11/11/2016 | 94,28 | 95,25 | 89,97 | 92,00 | -3,52% | 5,60% | 2.631.100 |
| 10/11/2016 | 94,07 | 97,93 | 94,06 | 95,36 | +2,67% | 4,11% | 4.130.900 |
| 09/11/2016 | 88,92 | 93,80 | 87,79 | 92,88 | +11,92% | 6,76% | 3.988.000 |
| 08/11/2016 | 82,73 | 84,21 | 81,85 | 82,99 | -0,28% | 2,85% | 1.768.000 |
| 07/11/2016 | 80,38 | 83,94 | 79,31 | 83,22 | +5,40% | 5,76% | 2.170.100 |
| 04/11/2016 | 77,39 | 80,92 | 77,39 | 78,96 | +1,63% | 4,56% | 1.902.100 |
| 03/11/2016 | 78,43 | 78,52 | 77,55 | 77,69 | -0,40% | 1,24% | 2.371.000 |
| 02/11/2016 | 77,60 | 78,43 | 76,77 | 78,00 | +0,15% | 2,14% | 2.580.400 |
| 01/11/2016 | 75,09 | 77,99 | 73,31 | 77,88 | +2,66% | 6,23% | 2.458.200 |
| 31/10/2016 | 77,61 | 77,88 | 75,77 | 75,86 | -2,22% | 2,72% | 1.928.200 |
| 28/10/2016 | 75,35 | 79,30 | 74,95 | 77,58 | +2,29% | 5,77% | 3.400.700 |
| 27/10/2016 | 79,39 | 81,05 | 75,01 | 75,84 | -3,65% | 7,61% | 3.549.000 |
| 26/10/2016 | 81,90 | 82,81 | 76,67 | 78,71 | +0,00% | 7,50% | 4.337.900 |